Amid the collapse of Theranos Inc. last year, investors are betting that some of the disgraced blood-testing startup’s lofty medical goals might still have a kernel of promise — at other companies. Grail, a company backed by Bill Gates and Jeff Bezos, said on Thursday that it’s expecting to raise a record $1 billion on the promise of a blood test to detect early-stage cancer.